WA-ECHODYNE
23.6.2021 18:02:14 CEST | Business Wire | Press release
Echodyne , the radar platform company, announced today substantial enhancements to its industry-leading radars, adding a new radar for international markets, a new product for special operations-type applications, a ruggedized radome, and continuing improvements in software and performance. Together, these product developments represent significant advancements to its breakthrough radar technology, MESA®. With customers in defense, national security, and critical infrastructure protection, Echodyne radars have become a core component for counter-UAS, border security, and base and perimeter 3D surveillance solutions.
The products and improvements include:
- EchoGuard International. The new EchoGuard radar has RoHS3 construction and is compliant with CE Radio Equipment Directive (RED) compliance for EU customers, per Type Examination Certificate per 2014/53/EU Radio Equipment directive.
- EchoGuard spectrum expansion. Many jurisdictions allow for RadioLocation use at 24.05-24.25 GHz, and EchoGuard now has a new product variant to address these markets.
- Improved radome. A ruggedized radome designed to withstand 1.5 joules of impact energy without altering the radar’s form factor.
- Lightweight Deployment Kit (LDK). With customer demand running high for a lightweight system, the new LDK is designed to fit 10 hours of Intelligence, Surveillance, & Reconnaissance (ISR) activity, including radar, computer, and batteries, into a military backpack weighing <20 lbs.
- Firmware updates. All Echodyne radars are software-defined, and this update includes enhanced stability and greater ease of use and functionality.
- New waveform ideal for slow velocity resolution. Driven by customer demand, the new waveform is designed to detect and track very slow movement, like stealthy human walking, at greater than 1.5 miles.
- RadarUI update. We have significantly upgraded our radar user interface with extended product line support and faster field deployment for easy radar visualization.
“We continue to find excellent customer traction for our high-performance radars and are excited to add these new products and enhancements to the EchoGuard family,” said Eben Frankenberg, CEO of Echodyne. “Our breakthrough radars are now embedded in advanced situational awareness and weapons systems, force protection, base and asset 3D perimeter surveillance, and critical infrastructure security. We are scaling our business to not only meet demand but to become the leading radar manufacturer for a range of current and future defense and security applications. There is a lot more to come and we’re excited about our next phase.”
For additional details and technical specifications, please visit our website at echodyne.com .
About Echodyne
Echodyne , the radar platform company, designs and delivers high-performance compact, solid-state, patent-protected MESA® radars. Ideally suited for defense, security, machine perception, and autonomy, Echodyne’s commercially priced electronically-scanned array radars are used by defense and government agencies, autonomous developers, and security integrators for counter-UAS, borders and perimeter security, critical infrastructure protection, unmanned aerial vehicles, and autonomous vehicles. Privately held, the company is based in Kirkland, Washington, and is backed by Bill Gates, NEA, Madrona Venture Group, Vulcan Capital, Vanedge Capital, and Lux Capital among others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005315/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom